Edgar Filing: PANACOS PHARMACEUTICALS, INC.

Amendment No. 1 to Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

Amendment No. 1

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2006

PANACOS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-24241

11-3238476

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

134 Coolidge Avenue

Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (617) 926-1551

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(a) Not applicable.

(b) Not applicable.

(d) On a Current Report on Form 8-K dated October 27, 2006, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that Laurent Fischer, M.D. was appointed as a director of the Company on October 25, 2006. By this reference, the contents of that Current Report are incorporated herein. On February 21, 2007, Dr. Fischer was appointed to the Nominating and Governance Committee of the Board of Directors.

(e) Not applicable.

(f) Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	PANACOS PHARMACEUTICALS, INC.

Dated: February 27, 2007	By:	/S/ PEYTON MARSHALL
		Peyton Marshall, Ph.D. Executive Vice President and Chief Financial Officer